UEG WEEK 2024

Did we get the pharmacogentics of drugs right?

TL1A - a hot new target?

S1P modulators - dead or alive?

The battle of IL-23s

The new kids on the block

S1P modulators - efficacy, safety and the future evolution

Hot topic deescalation - patients' wish & scientific evidence

What is early disease? Getting the right drug to the right patient

A focus on bowel urgency

P19 antagonists - on the way to disease clearence!?

Prime time for ultrasound use

How to treat extraintestinal manifestations?

JAKies side effects - what is the current place for JAKies?

RW data of Ustekinumab and the role of biosimilars

Fatigue - still a black box?

Long term persistence of Ustekinumab in moderate to severe Crohn’s disease

Mirikizumab is able to induce disease clearance in UC

Tofacitinib is effective in UC associated spondyloarthropathy

Tamuzimod for long term extension

anti-TL1A in UC

Guselkumab in UC - QUASAR maintenance data

Impact of Guselkumab maintenance on histological and endoscopic outcomes in UC

Guselkumab bei Colitis ulcerosa - die QUASAR Maitenance-Daten

Παρατεταμένη ανταπόκριση στο ustekinumab ασθενών με μέτρια προς βαρειά νόσο του Crohn

Tamuzimod per estensione a lungo termine

anti-TL1A nella CU

Guselkumab in patients with Crohn´s disease

Real world data on Risankizumab effectiveness in CD

Effects of Mirikizumab & Ustekinumab on histological inflammation in CD

Risankizumab efficacy in CD

Risankizumab in CD – expectations vs. reality

Dati real-world di efficacia di Risankizumab in malattia di Crohn

Guselkumab nei pazienti con malattia di Crohn

Ryzankizumab w chorobie Crohna – oczekiwania vs. Rzeczywistość

Efficacité du risankizumab dans la maladie de Crohn

How to diagnose PSC associated to IBD

How to diagnose PSC associated to IBD

Dose adjustment for subcutaneous Infliximab

Evidence based surgery for IBD?

Comment diagnostiquer la CSP associée aux MiCi ?

Dosisanpassung bei subkutanem Infliximab

Comment diagnostiquer la CSP associée aux MiCi?

כירורגיה מבוססת ראיות במחלות מעי דלקתיות?

Extended induction treatment in active UC can capture non responders to Mirikizumab

Long-term extension of Mirikizumab - significant added benefit!

Live biotherapeutic product for acute pouchitis

Long-term extension of Mirikizumab - barely any steroids needed!

Extended induction response in week 12 in non-responder patients with Mirikizumab

What treatment after Vedolizumab in UC?

Long-term Extension von Mirikizumab - deutlicher Zusatznutzen!

Quel traitement après le Vedolizumab dans la RCH?

Παράταση της θεραπείας εφόδου αυξάνει την ανταπόκριση στο miricizumab ασθενών με ενεργό ελκώδη κολίτιδα

Long-term Extension von Mirikizumab - kaum noch Steroide notwendig!

Levend biotherapeutisch medicijn voor acute pouchitis

Induzione prolungata con Mirikizumab in pazienti che non raggiungono una risposta clinica a 12 settimane

Vedolizumab in early CD

Data on interaction between biologics and post-operative recurrence

Ileocecal resection in CD – GI functional consequences

Early disease loves Vedolizumab

Vedolizumab is more effective in early Crohn´s disease

Early treatment with Vedolizumab in patients with CD

Früher Einsatz von Vedolizumab bei Patienten mit Morbus Crohn

Interactions entre le traitements biologiques et la chirurgie

Zaburzenia czynności przewodu pokarmowego po resekcji ileocekalnej w chorobie Crohna

Efficacité du vedolizumab dans les formes précoces

De efficaciteit van vedolizumab is beter bij vroege ziekte van Crohn

Divine support for intestinal fibrosis in UC & CD

Tulisokibart - a new therapeutic option in UC

Tulisokibart - new anti-TL1A agent for treating CD

Topical JAKies - let's try again!

RXC008 - novel mechanism of action for fibrostenosing Crohn´s disease

Cellular therapies in IBD - Old and New

Tulisokibart - eine neue Therapieoption bei CU

טיפולים תאיים במחלות מעי דלקתיות-ישן וחדש

RXC008 - un nuovo meccanismo d’azione per la malattia di Crohn fibrostenosante

Tulisokibart - un nuovo anti-TL1A per il trattamento della malattia di Crohn

Dezidierte Unterstützung bei intestinaler Fibrose bei UC & CD

Topische JAKies - auf ein Neues!

Long term safety of ozanimod in UC

Thiopurines and risk of cancer in IBD

Mirikizumab improves fatigue in patients with CD

Colorectal cancer risk and biologicals in IBD patients

Tiopuryny a ryzyko onkologiczne w IBD

Risico op colorectaal carcinoom bij IBD patienten onder biologische therapieen

IBS overlapping IBD

Upadacitinib normalizes health-related quality of life of patients with active moderate to severe UC

Positive effect of biologics on bowel urgency

VERDICT - Update on week 32 data

IBS overlapping IBD

VERDICT Update: Daten nach Woche 32

Biologika haben positiven Effekt auf den Stuhldrang

Το Upadacitinib αποκαθιστά την ποιότητα της ζωής ασθενών με μέτρια προς βαρειά ενεργό ελικώδη κολίτιδα

Whole food diet is more tolerable and equal to exclusive enteral nutrition in children with CD

Impact of diet on risk of disease flare in CD

Focus on nutrition

תזונה במוקד העניין

Strange collagen fragments as potential non-invasive biomarkers in gut fibrosis

Seltsame Kollagenfragmente als potenzielle nicht-invasive Biomarker bei Darmfibrose